BEAM Beam Therapeutics Inc
Company Analysis
Latest News
🟢 BEAM is trading 4.9% up today on breakout momentum and broader market strength
BEAM is trading 4.93% up now at $36.52 as it extends a strong upward run driven by continued buying pressure and broader risk-on sentiment. • The move appears...
🟢 BEAM extends move to 5.4% up
BEAM is trading at $35.75, up 5.4% versus the comparison close of $33.93 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 BEAM surges 4.7% following recent FDA clearance for BEAM-304 gene-editing trial
Beam Therapeutics (BEAM) is trading 4.7% up today at $35.53. This follows recent positive developments for its gene-editing pipeline: * The U.S. FDA...
🟢 Beam Therapeutics Inc is trading 4.22% up
BEAM is trading at $35.33, up 4.22%.
🟢 BEAM is trading 4.1% up today extending a multi-day rebound on positive BEAM-302 trial data momentum
BEAM is trading at $35.28 (4.1% up), extending a strong multi-day rebound from last week’s pullback as momentum continues to build. • Investors are continuing...
🟢 BEAM extends move to 6.9% up
BEAM is trading at $35.50, up 6.9% versus the comparison close of $33.20 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 BEAM is trading 4% up today as it rebounds from yesterday's sharp drop
BEAM is trading 4% up at $34.54 as the stock stages a partial recovery following yesterday’s significant decline. • The move follows a 6.6% drop in the...
🔴 BEAM extends move to 5.1% down
BEAM is trading at $33.71, down 5.1% versus the comparison close of $35.53 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 BEAM is trading 4.1% down today on profit-taking amid a broader market selloff
BEAM is trading 4.1% down today at $34.09 after a strong multi-day rally, as a broader risk-off tone hits technology and growth names. - The move aligns with...
🟢 Beam Therapeutics Inc is trading 4% up today after FDA clearance for its PKU gene-editing trial
Beam Therapeutics Inc is trading at $33.78 (+4.00%) after the FDA cleared its Investigational New Drug (IND) application for BEAM-304, a base-editing candidate...
Beam Therapeutics Wins FDA Clearance for PKU Gene-Editing Trial
Beam Therapeutics received FDA clearance for its Investigational New Drug application for BEAM-304. This approval allows the company to initiate a Phase 1/2...
🟢 Beam Therapeutics Inc extends move to 5.5% up
BEAM is trading at $32.70, up 5.5% versus the comparison close of $30.99 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Beam Therapeutics Inc is trading 4.3% up today as analysts highlight upcoming clinical catalysts
Beam Therapeutics Inc is trading 4.3% up at $32.33 as the stock extends its recent gains following positive Wall Street commentary and new analyst coverage. •...
🟢 Beam Therapeutics Inc is trading 6.6% up today amid a broad risk-on market rally
Beam Therapeutics Inc is trading 6.63% up at $30.95 as the market opens, tracking a broad risk-on rally across major indices. • Major benchmarks including the...
🟢 Beam Therapeutics Inc is trading 4.3% up today on broader risk-on sentiment and a modest rebound
Beam Therapeutics Inc is trading 4.3% up at $30.29 in pre-market, modestly rebounding from its recent pullback as part of a broader market rally. • The move...
🔴 Beam Therapeutics Inc is trading 4.2% down today amid broader risk-off sentiment ahead of U.S. CPI data
Beam Therapeutics Inc is trading at $29.20 (down 4.2%) in pre-market, giving back a portion of its recent rebound as broader market sentiment turns...
🟢 Beam Therapeutics Inc is trading 4% up today as markets rebound from macro-driven selling
Beam Therapeutics Inc is trading 4% up at $30.97 in early session trading, rebounding modestly after recent double-digit swings over the past week. • The move...
Beam Therapeutics Shareholders Approve All Proposals at 2026 Annual Meeting
Beam Therapeutics announced the official voting results from its 2026 annual meeting of stockholders held on June 3, 2026. All proposals presented to...
🟢 Beam Therapeutics Inc. trades 5.4% higher on positive BEAM-302 clinical data and accelerated FDA path potential
Beam Therapeutics Inc is trading about 5.4% up in pre-market near $31.00, driven by positive clinical news. • News from June 7 indicated that new data from...
🔴 Beam Therapeutics Inc is trading 10.9% down today on broader risk-off sentiment and rate fears
Beam Therapeutics Inc is trading 10.9% down at $29.25 today as broader market indices slide on stronger-for-longer interest rate fears. • The decline sees the...